Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2006 Apr;7(4):381-8.

Anti-CD3 antibody MacroGenics Inc.

Author information

1
Paddock Laboratories Inc, 3940 Quebec Avenue North, Minneapolis, MN 55427, USA. wbrown@paddocklabs.com

Abstract

A non-FcR-binding anti-CD3 monoclonal antibody, hOKT3gamma1 (Ala-Ala), originally developed by Columbia University, is being developed by MacroGenics for the potential treatment of type 1 diabetes and autoimmune diseases. Phase I/II trials in patients with diabetes have been completed, and a phase II clinical trial in psoriatic arthritis was initiated in October 2005. A Phase II trial that will evaluate a multi-course study of the drug in patients with new-onset diabetes began in March 2006. MacroGenics is currently seeking to outlicense the project to a strategic partner.

PMID:
16625825
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center